- Pfizer (PFE -0.2%) says a clinical study measuring the efficacy and safety of its treatment to help smokers quit met its primary and secondary endpoints.
- The study found patients treated with PFE's Chantix or Champix smoking cessation products (varenicline) were more likely to continue abstinence in the final weeks of the study than those without.
- Chantix/Champix was approved by the FDA in 2006 for people 18 and older.
Pfizer treatment to stop smoking meets endpoints
Jan 21 2014, 10:58 ET